Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial…

StudyOcular immunology and inflammation· Jul 2026

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Jiantong Du, Chen Xing, Zonghui Ma, Zhiyue Zhang

CorneaStudyClinical practiceQ2IF 1.7

Brolucizumab shows a massive reporting signal for retinal vasculitis versus other anti-VEGF agents.

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Jiantong Du … Zhiyue Zhang

Ocular immunology and inflammation · Jul 2026 · Q2 in Ophthalmology

Background

The safety profiles of high-dose intravitreal anti-vascular endothelial growth factor (VEGF) agents remain incompletely characterized.

Purpose

This study aimed to compare ocular adverse events, especially intraocular inflammation, associated with brolucizumab, faricimab, and 8 mg aflibercept.

Methods

Adverse event reports for high-dose anti-VEGF agents were extracted from the FDA Adverse Event Reporting System (FDA Adverse Event Reporting System) database.

n = 8,470 reports

Results

ROR = 7,451.51

Reporting odds ratio measures signal strength; higher values mean much more frequently reported than expected.

n = 8,470 reports

More results

Among 8,470 reports where high-dose anti-VEGF agents were designated as primary suspects, intraocular inflammation (intraocular inflammation) was the primary adverse reaction.

“

Conclusion

Intraocular inflammation profiles differ significantly among high-dose anti-VEGF agents. Comprehensive evaluation of individual patients' risk factors is recommended to guide clinical decision-making.

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Comparison of Intraocular Inflammation Associated with High-Dose Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Real-World Disproportionality Analysis.

Related papers